Clinical Trial Search

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39 — 7.4; 7.9; 7.8; 10.2 pmol/l

Primary: Maximum Insulin Concentration (Cmax) - First Phase Response — 233; 689; 74.3; 401 picomole per liter (pmol/L) — p=<0.001

Primary: Glucagon Response to Induced Hypoglycemia — 4.8; 8.8; 5.8; 4.2 pg/mL

Primary: Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose — 9.73; 8.03 ng/min — p=<0.001

Primary: Insulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion — 191; 171 nmol/min per 300 min — p=0.02

Primary: Insulin Secretion — 56766 pmol/l * 90 minutes

Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min

Primary: The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy. — 0.25 proportion of participants — p=< 0.05

Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min

Primary: Endogenous Glucose Production (EGP) — 4.99; 5.02; 6.82; 5.52 umol/kg/min

Primary: Fasting Insulin — 12.7; 13.1; 16.4; 13.9 μU/mL

Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005

Primary: Arginine-stimulated Insulin Secretion With and Without GLP-1 Blockade — 320.1; 243.4; 280; 251.2 pmol/L — p=< 0.05

Primary: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days — 0.41; 0.23; 1135.7; 309.0 index

Primary: Postprandial Glucose Area Under the Curve (AUC) — 1341; 1463 mmol/L*t

Primary: Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml) — 214; 149; 133; 188.5 μU/ml — p==0.1

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001

Primary: First Phase of Insulin Secretion — 13.8; 15.9 µU/ml

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05

Primary: Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF]) — -9.99; 7.98 % Change of Baseline Insulin…

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 57; 5; 6; 0 participants

Primary: Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose — 2.14; 1.49; 0.53; 2.95 (ng/min) / (mg/dL) — p=<0.001

Primary: Change in Endogenous Glucose Production (EGP) After Acute Exposure to a Single Dose and Again After 16 Weeks of Treatment — -0.18; 0.14; -0.08; -0.03 mg/kg.min

Primary: Disposition Index — 708; 793; 791 unitless

Primary: Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject — 3.8; -1.8; 7 mg/dL — p=0.000016

Primary: Difference in Glucose Tolerance Between Morning at 7:00 AM and Evening at 7:00 PM — 163; 203 mg/dl — p=0.02

Primary: Change in Plasma Glucose Concentration — -29.7; -17.2; 3.1; 0.9 mg/dl